Keymed completed Phase 2 trial of CM512, a TSLP x IL-13 bispecific antibody for chronic sinusitis
The Phase II clinical trial of long-acting TSLP x IL-13 bispecific antibody CM512 for the treatment of chronic sinusitis with nasal polyps (CRSwNP) has met all study endpoints.
GenFleet launches world’s first Phase 3 study of an oral KRAS G12D inhibitor for the treatment of NSCLC
GenFleet Therapeutics today held a national investigator conference for its Phase III registrational clinical trial of GFH375 (an oral KRAS G12D inhibitor) as monotherapy for non-small cell lung cancer (NSCLC) (“Kylin-Flight 01”). “Kylin-Flight 01” is a…
Hansoh’s HS-20093 met its Phase 3 goals, strengthening its status as a top B7-H3 ADC contender.
In less than a month, Hansoh Pharmaceutical‘s B7-H3 targeted antibody-drug conjugate (ADC) HS-20093 (Risvutatug Rezetecan) achieved two globally significant clinical breakthroughs. On July 28, Hansoh announced that the ARTEMIS-011 Phase III…